FDASmart Inc. Presents Day long forum/conference on 27th Sept 2011 at ITC Grand Central Hotel, Parel, Mumbai - India.
BioPharma IT - Next Generation:
Will India Lead or Follow?
September 27th, 2011 – Full Day Agenda:
| 8:30 a.m - 9:40 a.m : | Registration – Networking |
| 9:40 a.m - 9:45 a.m : | Opening Remarks / Welcome
Mr. Ram Balani CEO-Founder- FDASmart Inc. (Event Organizer) |
Session 1 :
| Emerging trends in computational genomics | |||
| 9:45 am - 10:15 a.m : | Mr. Sandeep Saxena - Founder & CEO - Acton Biotech Pvt Ltd. | ||
| Description : | The entire space of genomics today is heavily dependent on computing hardware and software. We use large computing powers, huge storage capacity, high resolution scanners, advanced artificial intelligence software and powerful databases to deliver results. In my talk, I will try and give an over view of the past and the future. | ||
| Speaker Background : |
|
||
Session 2 :
Session 3 :
| 11:00 a.m - 11:30 a.m : | Mr. Mohar Tiwari - Vice President - Information Technology - Glenmark Pharmaceuticals Ltd. |
||
| Description : | |||
| Speaker Background : |
|
||
Session : 4
| IT Imperatives for Life Sciences Organization | |||
| 12:00 p.m - 12:30 p.m : | Mr. Gopal Rangaraj - CIO - Reliance Life Sciences | ||
| Description : | The diversity of business necessitates provisioning of differentiated solution to address It automation needs of different business. E.g. Bio Pharma and Pharma business operations are supply chain intensive and need end to end supply chain solutions, the research groups require a long term It system to help them capture and analyze research related data. Enterprise Applications such as SAP R/3, Documentum address business requirements of RLS in parts and require to be interfaced with other point solutions such as Oracle Clinical and bespoke applications through an integrated architecture. RLS IT endeavors to deploy such software suites / technology initiatives to address these needs. RLS IT has progressively over the years deployed a number of software systems to support the above businesses with software needs.
The growth of internet and growth of social computing platforms, present a number of new technology options that show promise of adoption at RLS. New technology options such as Web 2.0 aim at providing a platform for the users to share and create content. Organizations across world have leveraged emerging technology to further their research, innovation and reach out to customers and entities engaged in business. These include deployments such as Social media, collaboration suites, Mobile computing and a pilot initiative for Cloud. |
||
| Speaker Background : |
|
||
Session 5 :
| Engineering Successful Life Sciences Enterprises with innovative IT solutions | |||
| 12:30 p.m - 1:00 p.m : | Dr. Reena Gollapudy - Lead Consultant - Infosys Ltd. | ||
| Description : | Notwithstanding scientific progress, the life sciences canvas today is significantly complex and constantly evolving. Impending changes such as, shrinking new drug pipelines vs. rising drug discovery costs, patent expirations and generics vs. mergers, acquisitions and externalization, compliance vs. competitiveness, and social media vs. traditional sales. Not surprisingly, the mantra for success lies in design and implementation of efficient business and cost models, with a focus on enterprise-wide innovation.
Life sciences organizations are in acute need of information systems that can handle enormous amounts of data in a stable, reliable, and, above all, secure way. Pharma, medical devices, biotechnology and related industries, need an effective and innovative IT strategy that will enable them to control compliance costs while improving business performance as they work to bring new products to the market. Key aspects of enterprise applications and solutions, such as cloud-based offerings, SaaS, IaaS, PaaS models, solution architecture, data security, and system integration and compatibility with internal systems have been successfully addressed to fulfill the new age demands of the Life Sciences sector. My talk will attempt to present these innovative perspectives and changes effected and will enable an apt showcase of the successful adoption of novel IT strategies by the transforming Life Sciences industry. |
||
| Speaker Background : |
|
||
Session 6 :
| Project and Risk management in Clinical Data Management | |||
| 2:00 p.m - 2:30 p.m : | Dr. Arshad Mohammed - Director-Clinical Data Management - Quintiles. | ||
| Description : | Clinical Data project management has complex interactions across functions like Clinical Project Management, Clinical Operations, Drug Safety, IVRS, Labs, ECG, Biostatistics, Medical Writing, etc. And with varied outsourcing across each of the functions - the project management and risk management of CDM projects assumes critical importance. Global Data Management at Quintiles has developed a technology solution to manage the operations and risk for hundreds of our projects. We use this unique system across all global DM sites. System also provides the Leadership live and dynamic reports of each project, DM lead, CDM site, customer, etc. Longitudinal data and reports also help us assess the trends in a number of key elements like delivery, risk, documentation, quality etc for each project. | ||
| Speaker Background : |
|
||
Session 7 :
| Working in the Cloud - Safe, Secure, Fast & Auditable Spotlight on Licensing, Clinical Trials & Safety document distribution | |||
| 2:30 p.m - 3:00 p.m : | Mr. Harvinder Singh - Founder & CEO - VSell Solutions | ||
| Description : | |||
| Speaker Background : |
|
||
Session 8 :
| Bioinformatics & Immunoinformatics: enabling design & development of next generation vaccines | |||
| 3:00 p.m - 3:30 p.m : | Dr. Urmila Kulkarni Kale, Bioinformatics Centre, University of Pune | ||
| Description : | Emergence and growth of bioinformatics in the last twenty-five years is one of the landmark events in the history of Science. It has added a third dimension of ‘in silico’ to the existing ‘in vivo’ and ‘in vitro’ approaches to study life and its processes. The informatics facilitates transformation of biological data to information and knowledge with an ultimate objective to discover new drugs and vaccines. Bioinformatics and Immunoinformatics have brought a paradigm shift and reversed the process of vaccine development, which is termed as reverse vaccinology approach. The advent of next generation sequencing technologies are further offering unprecedented opportunities for data driven, knowledge-based approaches for rational design of viral vaccines. The three major components of reverse vaccinology are genomic data of viruses, various bioinformatics/immunoinformatics prediction programs and availability of three-dimensional structures of viral proteins. These are independent domains of research in themselves, which are also inter-dependant and together offer distinct advantages in designing vaccines. A detailed account of the state of the art resources and methods in each of these domains will be provided with appropriate case studies to substantiate their role in vaccine design. Furthermore, the challenges viz. varying efficacy of existing vaccines also needs to be addressed as viruses are known to evolve at a higher rate as compared to other species and will be discussed. |
||
| Speaker Background : |
|
||
Session 9 :
| Innovative Uses Of Technology To Bring Together Patients-Pharma- Health Professionals | |||
| 3:30 p.m - 4:00 p.m : | Dr. Neelesh Bhandari - Chief Consulting Officer - Digital MedCom. | ||
| Description : | Technology has become ubiquitous. Healthcare consumers and healthcare professionals now have access to a number of paradigm shifting technologies which has changed the way business is done in the pharma-healthcare continuum. Cloud computing, touch screens and personal health records dictate that we need to become more and more patient centric in our approach. The goal of all healthcare reforms is to bring the industry closer to the end consumer and cut down on intermediaries. Dr. Neelesh Bhandari looks at new and innovative ways these technologies can be used to create value for all stakeholders, i.e for the doctors, patients and the pharmaceutical industry. | ||
| Speaker Background : |
|
||
Panel Discussion : :
| Ram introduce Dipta Chaudhury – Dipta to moderate | |||
| 4:30 p.m - 5:30 p.m : | |||
| Description : | |||
| Speaker Background : | |||
| 5:30 p.m : | Frost & Sullivan & FDASmart White Paper Release - CD Hand-outs |
| 5:45 p.m : | Conference Concludes |
Speakers
Sponsor
Knowledge Partner
Companies Attending
Waiting Approval ....









